1 Department of Medicine, Division of Oncology and 2 Department of Internal Medicine, University of North Dakota School of Medicine; 3 Department of Medicine and 4 Department of Pathology, Meritcare Health System, Fargo, ND; 5 Department of Pathology, IMPATH Laboratories, Los Angeles, CA, USA
Received 28 October 2002; revised 9 January 2002; accepted 18 February 2003
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The aim of this study was to determine the incidence and role of CD117 (c-KIT) overexpression as a predictive/prognostic marker in extensive-stage small-cell lung carcinoma (ESSCLC). We performed a retrospective study on subjects with a biopsy-proven diagnosis of ESSCLC.
Patients and methods:
A chart review for demographic and clinical data was performed on patients with ESSCLC diagnosed between 1991 and 2001. CD117 overexpression was evaluated using immunohistochemistry (A4052 polyclonal antibody) performed on archival paraffin-embedded specimens.
Results:
Two hundred and twenty-three patients with ESSCLC were identified, of whom 193 (84 females, 109 males) with a mean age of 68.5 years (range 4290) had adequate tissue specimens available for CD117 testing. The most commonly presenting symptom was weight loss, seen in 61 patients (31.6%). Of the 193 specimens, 54 (27.9%) showed CD117 overexpression. The median length of survival for CD117-positive patients was 9 months as compared with the CD117-negative population, in whom the survival was 6 months (P = 0.025, Cox proportional hazard method).
Conclusions:
CD117 overexpression detected using immunohistochemistry is observed in about a third of patients with ESSCLC and does not have statistically significant prognostic value. However, CD117 may be a potential target for site-specific immunotherapy in ESSCLC. Our findings suggest a role for clinical trials assessing the role of selective tyrosine kinase inhibitor STI-571 (alone or in combination with conventional therapy) in patients with ESSCLC.
Key words: c-kit, extensive stage, small-cell lung carcinoma, survival
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
To understand the biological basis for the rapid progression of SCLC, biochemical, serological, cytogenetic and molecular studies have been conducted and the understanding of carcinogenesis of SCLC has rapidly evolved [6, 7]. Growth deregulation in human SCLC has been attributed to many genetic abnormalities, including mutation/deletion of tumor suppressor genes, the existence of multiple autocrine growth loops, and the amplification and overexpression of various proto-oncogenes.
The proto-oncogene c-kit encodes a transmembrane tyrosine kinase receptor (c-KIT/CD117) related to the platelet-derived growth factor (PDGF)/colony-stimulating factor 1 (CSF-1) (c-fms) receptor subfamily [8]. CD117 is thought to play an important role in hematopoiesis, spermatogenesis, melanogenesis and, more recently, in carcinogenesis [911]. Overexpression of CD117 has previously been documented in myeloid leukemia, neuroblastoma, breast tumor, colon tumors, gynecological tumors, testicular germ cell tumors and SCLC [1215]. However, few studies have addressed the prognostic implication of CD117 overexpression in the select population of patients with ESSCLC. To determine the incidence and role of CD117 overexpression as a predictive/prognostic marker in ESSCLC, we performed a retrospective study on subjects with a biopsy-proven diagnosis of ESSCLC.
![]() |
Patients and methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
CD117 testing performed using IHC was recorded on a semi-quantitative scale to record the number of positive cells (10%, 1050% and >50%) and the intensity of reaction. CD117 status was reported as positive if it was >10% and negative if it was <10%. Imunohistochemical staining for c-KIT (CD117) was performed using a 1:250 dilution of the rabbit polyclonal antibody A4502 (IMPATH, Los Angeles, CA, USA) with the EnVision detection system (IMPATH). An antigen retrieval method was not utilized. Appropriate positive and negative controls were used throughout the testing process. We used the A4502 antibody because it has shown consistent performance with a low background, because it seems to be the most widely used Kit antibody, and because it is the antibody specified for CD117 testing in the large cooperative clinical trials of selective tyrosine kinase inhibitor STI-571. All interpretation of CD117 testing was performed by a single pathologist who was blinded from the clinical data of patients in our study population.
Two hundred and twenty-three patients with a biopsy-proven diagnosis of ESSCLC were identified from our database. Overall survival was calculated by the KaplanMeier product limit method from the date of diagnosis of lung carcinoma. After adjusting for age, smoking history, performance scores, presence of weight loss and therapy, a multivariate analysis using the Cox proportional hazard method was performed to analyze the prognostic impact of CD117 overexpression. Statistical analysis and survival curves were obtained using SPSS-10 for Windows.
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
|
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Transmembrane protein-tyrosine kinases play an important role in the regulation of cell growth as receptors for growth factors [18]. CD117 encodes a transmembrane tyrosine kinase receptor that is structurally similar to the receptors for CSF-1 and PDGF [8, 15]. Previously, several small studies have indicated a preferential expression of CD117 proto-oncogene in SCLC [1927], but none describes the prognostic implication of CD117 overexpression in ESSCLC. In an attempt to elucidate the predictive role of IHC determination of CD117 overexpression in patients with ESSCLC, we assessed CD117 status on pathological lung specimens in the largest reported cohort of patients with biopsy-proven ESSCLC.
Of the 193 specimens in our study, 54 (27.9%) showed CD117 overexpression by IHC. The incidence of overexpression in our population was lower then previously reported. Hibi et al. [28] reported that over 60% of SCLCs overexpress CD117. In another series, Sekido et al. [21] reported a higher incidence of CD117 overexpression (81%) in SCLC. The reason for the difference in our findings and the previous reports may be attributable to the fact that our large study included only patients with ESSCLC. Thus, although the presence of CD117 does not carry definite prognostic value, it is possible that overexpression may be preferentially observed in patients with limited-stage SCLC, in whom the biology of lung carcinoma is different compared with ESSCLC. But, more importantly, the earlier reports used northern or western blotting techniques for assessing CD117 expression; both northern and western blotting are more sensitive but less specific than IHC techniques [29, 30].
The median survival in patients with CD117 overexpression was 16.5 months as compared with the CD117-negative population, in whom survival was only 14 months. After adjusting for age, performance status, smoking history, presence of weight loss as a symptom and therapy, the survival difference was not statistically significant (P = 0.025, Cox proportional hazard multivariate analysis). Also, interestingly, men were more likely to have CD117 overexpression than women. This intriguing finding will need to be validated in future trials. Thus, CD117 may play a role as a target for site-specific therapy; however, it lacks definitive prognostic value in patients with ESSCLC.
![]() |
Conclusion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
![]() |
Acknowledgements |
---|
![]() |
Footnotes |
---|
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
2. DiLoreto C, DiLauro V, Puglisi F et al. Immunocytochemical expression of tissue specific transcription factor-1 in lung carcinoma. J Clin Pathol 1997; 50: 3032.[Abstract]
3. Chute JP, Chen T, Feigal E et al. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999; 17: 17941801.
4. Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet 2000; 355: 479575.[CrossRef][ISI][Medline]
5. Chute JP, Venzon DJ, Hankins L et al. Outcomes of patients with small-cell lung cancer during 20 years of clinical research at the US National Cancer Institute. Mayo Clin Proc 1997; 72: 901912.[ISI][Medline]
6. Takahashi T, Obata Y, Sekido Y et al. Expression and amplification of myc gene family in small cell lung cancer and its relation to biological characteristics. Cancer Res 1989; 49: 26832688.[Abstract]
7. Birrer MJ, Minna JD. Molecular genetics of lung cancer. Semin Oncol 1988; 15: 226235.[ISI][Medline]
8. Yarden Y, Kuang WJ, Yang-Feng T et al. A human proto-oncogene c-Kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 1987; 6: 33423351.
9. Natali PG, Nicotra MR, Sures I et al. Expression of c-kit receptor in normal and transformed human nonlymphoid tissues. Cancer Res 1992; 52: 61396143.[Abstract]
10. Sorrentino V, Giorgi M, Geremia R et al. Expression of c-kit proto-oncogene in the murine male germ cells. Oncogene 1991; 6: 149151.[ISI][Medline]
11. Pietsch T, Nicotra MR, Fraioli R et al. Expression of the c-Kit receptor and its ligand SCF in non-small cell lung carcinomas. Int J Cancer 1998; 75: 171175.[CrossRef][ISI][Medline]
12. Ikeda H, Kanakura Y, Tamaki T et al. Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. Blood 1991; 78: 29622968.[Abstract]
13. Clarke L, Demetri G, Leitzel K et al. Soluble c-KIT in the serum of patients with gastrointestinal stromal tumors (GISTs). Proc Am Soc Clin Oncol 2002; 21: 436a (Abstr 1741).
14. Barrios C, Kappes D, Ritt C et al. Clinical correlation of c-kit expression in small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 2002; 21: 302b (Abstr 3029).
15. Demetri GD. Targeting C-kit mutations in solid tumors: scientific rationale and novel therapeutic options. Semin Oncol 2001; 28: 1926.[Medline]
16. Minna JD, Kaye FJ, Takahashi T et al. Recessive oncogenes and chromosomal deletions in human lung cancer. In Cavenee W, Hastie N, Stanbridge E (eds):Current Communications in Molecular Biology: Recessive Oncogenes and Tumor Suppression. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press 1989; 5765.
17. Cuttitta F, Carney DN, Mulshine J et al. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature 1985; 316: 823826.[ISI][Medline]
18. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990; 61: 203212.[ISI][Medline]
19. DiPaola RS, Kuczynski WI, Onodera K et al. Evidence for a functional kit receptor in melanoma, breast, and lung carcinoma cells. Cancer Gene Ther 1997; 4: 176182.
20. Matsuda R, Takahashi T, Nakamura S et al. Expression of the c-kit protein in human solid tumors and in corresponding fetal and adult normal tissues. Am J Pathol 1993; 142: 339346.[Abstract]
21. Sekido Y, Obata Y, Ueda R et al. Preferential expression of c-kit proto-oncogene transcripts in small cell lung cancer. Cancer Res 1991; 51: 24162419.[Abstract]
22. Rygaard K, Nakamura T, Spang-Thomsen M. Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts. Br J Cancer 1993; 67: 3746.[ISI][Medline]
23. Plummer H, Catlett J, Leftwich J et al. C-myc expression correlates with suppression of c-kit proto-oncogene expression in small cell lung cancer cell lines. Cancer Res 1993; 53: 43374342.[Abstract]
24. Krystal G, Hines S, Organ C. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res 1996; 56: 370376.[Abstract]
25. Krystal GW, Honsawek S, Kiewlich D et al. Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells. Cancer Res 2001; 61: 36603668.
26. Krystal GW, Honsawek S, Litz J et al. The selective tyrosine kinase inhibitor STI 571 inhibits small cell lung cancer growth. Clin Cancer Res 2000; 6: 33193326.
27. Wang WL, Healy ME, Sattler M et al. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene 2000; 19: 35213528.[CrossRef][ISI][Medline]
28. Hibi K, Takahashi T, Sekido Y et al. Coexpression of the stem cell factor and the c-kit genes in small cell-lung cancer. Oncogene 1991; 6: 22912296.[ISI][Medline]
29. Hornick JL, Fletcher CD. Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. Am J Clin Pathol 2002; 117: 188193.[CrossRef][ISI][Medline]
30. Fletcher CD, Fletcher JA. Testing for KIT (CD117) in gastrointestinal stromal tumors: another Hercep test? Am J Clin Pathol 2002; 118: 163164.[CrossRef][ISI][Medline]